Comment Clock Runs Out on Medicare’s Fast-Track Device Coverage Plan
The public comment period closed Tuesday, October 13, on one of the most consequential Medicare coverage proposals in years, a joint CMS and FDA pathway called RAPID that would compress the timeline for covering breakthrough medical devices from years to months. The proposal, published in the Federal Register in August as notice CMS-3487-NC, would have Medicare issue a proposed national coverage decision on the same day the FDA authorizes an eligible device for market, fundamentally restructuring how the 70 million Americans who rely on Medicare gain access to new medical technology.
The Regulatory Alignment for Predictable and Immediate Device pathway, RAPID for short, targets a problem the device industry and patient advocates have complained about for decades. A device can win FDA authorization after rigorous clinical trials and still leave patients waiting years for Medicare to decide whether it will pay for it, because the national coverage determination process that governs Medicare’s coverage of major technologies runs on its own separate clock. RAPID proposes to synchronize the two clocks.
How the RAPID Pathway Would Work
Under the proposal, CMS would work with device manufacturers earlier in the development process, including around clinical outcomes evaluated in an investigational device exemption study that enrolls Medicare beneficiaries. That early involvement is the mechanism that makes speed possible later, because the evidence Medicare needs for a coverage decision would be generated during the trials that already support FDA clearance rather than collected afterward in a separate process.
The timing commitments are specific. For an eligible device, CMS would issue a proposed national coverage determination, an NCD, on the same day the FDA grants marketing authorization. The agency’s stated goal is a final NCD approximately 60 days after FDA authorization for eligible Class II devices and 90 days for eligible Class III devices, with a 30-day public comment period on the proposed decision along the way. For context, national coverage determinations for major technologies have historically taken a year or more.
Which Devices Qualify
RAPID is not open to every new medical device. The pathway is proposed for certain FDA Breakthrough-designated Class II and Class III devices, meaning technologies the FDA has already identified as offering more effective treatment or diagnosis for serious conditions. Class II devices are moderate-risk products regulated through the 510(k) pathway with special controls, while Class III devices are the highest-risk category, typically requiring premarket approval. The proposal also states that in vitro diagnostic products are not eligible for RAPID, and CMS attaches further conditions beyond the designation itself, including participation in the agency’s Total Product Life Advisory program and a planned De Novo submission for eligible Class II devices. Class III devices are not required to take part in that program.
The breakthrough designation filter matters. It means the pathway is aimed at devices the FDA has already fast-tracked through its own system, closing the gap between the two agencies’ treatment of the same technology rather than loosening clinical evidence requirements for everyone.
The Stakes for Medicare Beneficiaries
The Federal Register notice describes Medicare as serving nearly 70 million beneficiaries, with roughly 34 million, about 51 percent of the total, in Original Medicare as of 2025. Those beneficiaries skew older and sicker than the general population, and they are precisely the population most likely to need the cardiac devices, neurological implants and advanced imaging technologies that fill the breakthrough pipeline.
For a patient with a condition treatable by a breakthrough device, the difference between FDA authorization in month one and a final Medicare coverage decision in month twenty-four is the difference between waiting for a technology and using it. Patient advocacy organizations have made exactly this argument for years, and the comment docket reflects it. The Federal Register page showed dozens of comments in the weeks after publication, including formal comments from patients and advocacy groups urging CMS to finalize the pathway.
What the Comment Period Determines
The 30-day comment window that closed October 13 will shape whether and how RAPID becomes final. Comments on a procedural notice like this one influence implementation details, and the substantive comments on the proposed coverage framework itself feed the record CMS must build before finalizing. Applied Policy’s analysis of the proposal notes that CMS is reshaping multiple Medicare device pathways at once, and that the RAPID proposal arrives alongside other changes to how the agency evaluates device evidence.
Industry commenters are expected to focus on the eligibility definitions, the adequacy of the 60 and 90 day timelines for complex technologies, and how the parallel investigational device exemption study requirements will work in practice for manufacturers running global trials. Patient groups, meanwhile, are pressing for the broadest possible reading of which devices qualify, and for CMS to finalize quickly rather than let the pathway itself drift into the years-long process it is designed to replace.
Why CMS and FDA Are Doing This Together
The two agencies have overlapping authority over medical technology and historically non-overlapping timelines. The FDA decides whether a device is safe and effective enough to sell. Medicare decides whether it will pay for the device when prescribed for its beneficiaries. Because Medicare coverage decisions function as de facto national standards for how technologies are used in American medicine, the second decision often matters more to a manufacturer’s commercial fate than the first.
By aligning the processes, CMS and FDA are acknowledging that sequential review wastes time without protecting patients, since the evidence base is the same. The breakthrough device designation already identifies technologies with substantial clinical promise. RAPID proposes that Medicare should be ready to make its coverage call when the FDA’s call arrives, not start its clock at that moment.
What Happens After the Deadline
Once the comment period closes, CMS will review the submissions and decide whether to finalize the pathway, revise it, or issue a revised proposal. The agency has signaled its intent to accelerate patient access to life-changing medical devices, and the political pressure to deliver on that signal, from Congress, from the device industry and from patient groups, will shape the final rule’s contours.
For manufacturers of breakthrough devices, the practical impact will be visible in trial design and submission timing, since a pathway that coordinates FDA authorization with same-day Medicare proposals rewards planning for both processes at once. For the nearly 70 million people in Medicare, the impact will be measured in a single number that has defined their experience with new medical technology for decades: how long they have to wait after the FDA says a device works.
Frequently Asked Questions
What is the CMS RAPID coverage pathway?
RAPID, short for Regulatory Alignment for Predictable and Immediate Device Coverage, is a proposed CMS and FDA pathway that would have Medicare issue a proposed national coverage decision on the same day the FDA authorizes an eligible breakthrough device, with final coverage decisions targeted at 60 days for Class II devices and 90 days for Class III devices.
When did the public comment period close?
Comments on the RAPID proposal, published in the Federal Register on August 11, 2026 as CMS-3487-NC, closed on October 13, 2026. The Federal Register docket showed dozens of comments in the weeks leading up to the deadline.
Which devices would qualify for RAPID?
Certain FDA Breakthrough-designated Class II and Class III medical devices would be eligible, subject to further conditions such as participation in the FDA’s Total Product Life Advisory program and, for Class II, a planned De Novo submission. In vitro diagnostic products are not eligible under the proposal. Class II covers moderate-risk devices and Class III covers the highest-risk category requiring premarket approval.
How many people does Medicare cover?
Medicare serves nearly 70 million beneficiaries, with roughly 34 million, about 51 percent of the total, enrolled in Original Medicare as of 2025, according to the Federal Register notice.
